Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EBANGA

(Ansuvimab)

Monoclonal antibody

Emergent BioSolutions

0

Indications

2

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Ebola1 trial

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

Available·RRidgeback Biotherapeutics, LP··NCT05067166

Prophylaxis1 trial

Prophylaxis Vaccine Antibodies Ebola

Unknown status·AANRS, Emerging Infectious Diseases·Phase 2·NCT04822376·250 enrolled

Regulatory

FDA Approval Timeline[3]

Dec 21, 2020

EBANGA

BLA BLA761172

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ansuvimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ansuvimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (BLA BLA761172). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Emergent BioSolutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Company: Emergent BioSolutions

Related News